Dr Payam Sasannejad, Neurologist Assistant Professor of mums Intravenous thrombolytic therapy in acute ischemic stroke.

Slides:



Advertisements
Similar presentations
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Advertisements

Stroke Workshop Case Scenario.
Maternal Safety Bundle for Severe Hypertension in Pregnancy
Some Difficult Stroke Cases: What Would You Do?
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria
Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Hyperacute Stroke Management Canadian Best Practice Recommendations for.
Disclosures: Maximo C. Kiok, M.D. Medical Director of Stroke Program Trinity Health System.
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
Target: Stroke Building on Success A national quality improvement initiative of the American Heart Association/American Stroke Association to improve.
The cursor must be over the text in the question boxes to have the answers open correctly.
Stroke-treatment and management SAHD Naghme Adab.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Spotlight A Stroke of Error. This presentation is based on the December 2014 AHRQ WebM&M Spotlight Case –See the full article at
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
What neurologist may add to the care and cure of of stroke patients, or… Peter Sandercock Perugia December 2007 What is the place of the neurologist in.
Seeing a Stroke Developed by: K. Banasky, RN, BSN Educator GCH Emergency Services.
What can we do to cut down the time it takes to give a clot dissolving drug (tPA)?
Neuroimaging of Ischemic Stroke With CT and MRI
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
Time is still Brain Victoria Parada MD Clinical Director Neuroscience and Stroke Program Valley Baptist Medical Center Harlingen Management of Acute Ischemic.
 Describe the major signs and symptoms of stroke  Classify stroke and type specific treatments  Apply 8 d’s of stroke care  Follow suspected stroke.
Acute ischemic stroke: Not a moment to lose By Julie Miller, RN, CCRN, BSN, & Janice Mink, RN, CCRN, CNRN Nursing2009, May ANCC contact hours.
T. P.A. tissue Plasminogen Activator Presented by: Kelly Banasky, RN, BSN GCH Emergency Services Educator.
Care of Patient With Stroke Dr. Belal Hijji, RN, PhD November 19 & 23, 2011.
Administering Thrombolysis Early Management
Interventions in Acute Ischemic Stroke: Strategies for the New Millennium For the next 25 minutes, we will spend sometime talking about Neuroimaging.
Stroke and the ED Kurian Thomas, MD Department of Neurology.
The Evolving Management of Pediatric Stroke Christopher A. Miller, MD July 21, 2012.
S TPA and Appropriate documentation for contraindications: A conversation with The Joint Commission and a Physician Perspective Shyam Prabhakaran, MD,
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
Intra - Arterial Thrombolysis for acute stroke
Presented by: Passant Mounir Nagy Under the supervision of: Prof. Dr/ Seham Hafez.
Stroke Damrongsak Bulyalert, M.D., Ph.D.
Acute Stroke Management
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
STROKE Lalith Sivanathan 2015 ADVANCED CONCEPTS IN EMERGENCY CARE (EMS 483)
Subarachnoid Hemorrhage. Etiology Spontaneous (primary) subarachnoid hemorrhage usually results from ruptured aneurysms. A congenital intracranial saccular.
Case 60 F with PMH HTN, DM, CVA presented to UNC ED CC: seizure. Per the daughter the pt was walking and all of a sudden fell and her whole body started.
Intracerebral Hemorrhage
ALTERATIONS IN THE NERVOUS SYSTEM
Stroke : To Lyse or Not to Lyse ? Understand the Literature and Decide : What is best for your practice environment ?
Thrombolysis for acute ischaemic stroke Clinical
Primary Stroke Center EMS Training Union Hospital, Inc. Terre Haute Union Hospital, Inc. Terre Haute.
Kim, Sun-Yong, M.D. Department of Radiology Ajou University Hospital, Suwon, Korea AGGRESIVE MECHANICAL CLOT DISRUPTION FOR ACUTE ISCHEMIC STROKE WITH.
Protocol Nichol McBee, MPH, CCRP BIOS Coordinating Center Johns Hopkins University.
Jennifer Williams, PhD, RN, ACNS-BC Clinical Nurse Specialist Emergency Services Barnes-Jewish Hospital Acute Stroke Management and Interventions 2016.
“Door to Needle (DTN) Time in Stroke Thrombolysis” Audit Care of the Elderly Department Dr Nikoletta Petrou, Foundation Year 1 Doctor Dr Prasanna Aghoram,
Stroke Rami Unterman, M.D.. Objectives Define and differentiate the types of stroke Recognize the urgency involved in the evaluation and management of.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Simon Howard Medical Management of Acute Stroke. Fast Recognition of Stroke With sudden onset neurological symptoms: 'FAST' should be used to screen for.
ACUTE STROKE TREATMENT: An introduction Dec.2014
Stroke Protocol Time Lost Is Brain Lost!. Objective: Improve patient care & outcomes Offer a standard of care Increase efficiency Meet accreditation recommendations.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
S TROKE M ANAGEMENT A CCORDING TO B EST P RACTICE ……..it matters…….. 1.
Adult Stroke 2010 AHA Guidelines for CPR and ECC
Outpatient DVT assessment & treatment Daniel Gilada.
IN THE NAME OF GOD Dr. h-kayalha Anesthesiologist.
Management of Acute ISCHEMIC stroke
Acute Ischemic Stroke: Introduction to Diagnosis and Treatment
Advances in Treatment for Acute Stroke
ACLS CVA.
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
Stroke Niazy B Hussam.
Performance Improvement: Emergency Management in Acute Cerebrovascular Patients Current US Guidelines Lisa A. Shultz, MD Medical Director, Lourdes Stroke.
Updates in the Treatment of Acute Stroke
Approach to Hemorrhagic and Ischemic Strokes
ICU Book Chapter 46 ACUTE STROKE
The Multi-arm Optimization of Stroke Thrombolysis (MOST) Trial
Presentation transcript:

Dr Payam Sasannejad, Neurologist Assistant Professor of mums Intravenous thrombolytic therapy in acute ischemic stroke

1.9 million neurons 14 billion synapses 7.5 miles myelinated fibers In a Typical Acute Ischemic Stroke, Every Minute Until Reperfusion the Brain Loses:

Recanalization recanalization and restoration of cerebral blood flow : desired immediate result of thrombolytic therapy Recanalization is associated with improved outcome and reduced mortality in acute ischemic stroke Spotaneous Intravenous thrombolysis Intra-arterial thrombolysis Combined intravenous and intra-arterial thrombolysis Mechanical

Intravenous rt-PA is recommended for selected patients who may be treated within 3 hours of onset of ischemic stroke (Class I Recommendation, Level of Evidence A). rt-PA should be administered to eligible patients who can be treated in the time period of 3 to 4.5 hours after stroke (Class I Recommendation, Level of Evidence B). AHA/ASA Guideline Recommendations

"Time is brain" the sooner intravenous rt-PA treatment, the more likely it is to be beneficial

"Time is brain" Guidelines recommend that the elapsed time to the start of rt-PA infusion should be ≤60 minutes from the time of patient arrival in the emergency department

"Time is brain" The following in-hospital timeline is suggested as a goal for all patients with acute ischemic stroke who are eligible for treatment with intravenous rt-PA: ● Evaluation by physician - 10 minutes ● Stroke or neurologic expertise contacted, ie, stroke team - 15 minutes ● Head CT or MRI scan - 25 minutes ● Interpretation of neuroimaging scan - 45 minutes ● Start of treatment - 60 minutes from arrival

"Time is brain"  Other items that can lead to delay include: initial telephone triage by the stroke physician obtaining and waiting for results of blood and laboratory tests obtaining consent treating hypertension (ie, systolic blood pressure ≥185 mmHg or diastolic ≥110 mmHg) delivery of rt-PA from the pharmacy to the bedside

"Time is brain" In the United States 22 percent of all ischemic stroke patients present within 3 hours only about 8 percent meet all other eligibility criteria for rt-PA treatment

Eligibility criteria for the treatment of acute ischemic stroke with recombinant tissue plasminogen activator Inclusion criteria Clinical diagnosis of ischemic stroke causing measurable neurologic deficit Onset of symptoms <4.5 hours before beginning treatment; if the exact time of stroke onset is not known, it is defined as the last time the patient was known to be normal Age ≥18 years

Exclusion criteria Historical Significant stroke or head trauma in the previous three months Previous intracranial hemorrhage Intracranial neoplasm, arteriovenous malformation, or aneurysm Recent intracranial or intraspinal surgery Arterial puncture at a noncompressible site in the previous seven days

Exclusion criteria Clinical Symptoms suggestive of subarachnoid hemorrhage Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg) Serum glucose <50 mg/dL (<2.8 mmol/L) Active internal bleeding Acute bleeding diathesis, including but not limited to conditions defined in 'Hematologic‘

Exclusion criteria Hematologic Platelet count <100,000/mm 3 Current anticoagulant use with an INR >1.7 or PT >15 seconds Heparin use within 48 hours and an abnormally elevated aPTT Current use of a direct thrombin inhibitor or direct factor Xa inhibitor with evidence of anticoagulant effect by laboratory tests such as aPTT, INR, ECT, TT, or appropriate factor Xa activity assays

Exclusion criteria Head CT scan Evidence of hemorrhage Evidence of a multilobar infarction with hypodensity involving >33 percent of the cerebral hemisphere subtle or small areas of hypodensity, loss of gray-white distinction, obscuration of the lentiform nucleus, and the presence of a hyperdense artery sign

Relative exclusion criteria Only minor and isolated neurologic signs Rapidly improving stroke symptoms Major surgery or serious trauma in the previous 14 days Gastrointestinal or urinary tract bleeding in the previous 21 days Myocardial infarction in the previous three months Seizure at the onset of stroke with postictal neurologic impairments Pregnancy

Additional relative exclusion criteria for treatment from 3 to 4.5 hours from symptom onset Age >80 years Oral anticoagulant use regardless of INR Severe stroke (NIHSS score >25) Combination of both previous ischemic stroke and diabetes mellitus

The 2013 AHA/ASA guidelines: under some circumstances and with careful consideration of risk- to-benefit, patients may receive fibrinolytic therapy despite the presence of one or more relative contraindications physicians with expertise in acute stroke care may modify the eligibility criteria

consensus patients who have a persistent neurologic deficit that is potentially disabling, despite improvement of any degree, should be treated with tPA in the absence of other contraindications. following should be considered disabling deficits: ● Complete hemianopia: ≥2 on the NIHSS question 3 ● Severe aphasia: ≥2 on NIHSS question 9 ● Visual or sensory extinction: ≥1 on NIHSS question 11 ● Any weakness limiting sustained effort against gravity : ≥2 on NIHSS question 5 or 6 ● Any deficits that lead to a total NIHSS >5 ● Any remaining deficit considered potentially disabling by the patient, family, or the treating practitioner

rapidly improving stroke symptoms (RISS) as an exclusion for tPA treatment only for patients who improve to the degree that any remaining deficits seem nondisabling thrombolytic treatment should not be delayed by continued monitoring for improvement

Some experts advocate a more rational use of thrombolytic therapy based on pathophysiologic information from modern imaging studies vascular lesion and the location extent reversibility of brain ischemia Such an approach may be considered in expert stroke centers with access to modern MRI, CT, and ultrasound based technologies

Informed consent Some patients will accept any risk Others are more risk averse and prefer to accept disability discussion of the risks and benefits with the patient and family (neurologic deficits caused by acute stroke often preclude obtaining informed consent from the patient) rt-PA is an approved therapy for acute stroke; consent is not required to administer rt-PA as an emergent therapy for eligible patients if surrogate consent is not possiblert-PA

MANAGEMENT OF BLOOD PRESSURE Strict blood pressure control is critical prior to and during the first 24 hours after thrombolytic therapy The blood pressure must be at or below 185 mmHg systolic and 110 mmHg diastolic before administering rt-PA intravenous agents: labetalol or nicardipine Alternative agents: hydralazine and enalaprilat If intravenous treatment does not bring the blood pressure into the acceptable range, the patient should not be treated with rt-PA

Dosing A dedicated intravenous line is required for rt-PA, and all patients should have at least one additional large bore intravenous line ● The rt-PA dose is calculated at 0.9 mg/kg of actual body weight, with a maximum dose of 90 mg ● Ten percent of the dose is given as an intravenous bolus over one minute and the remainder is infused over one hour

Monitoring All patients should be admitted to an intensive care unit or stroke unit for at least 24 hours of close neurologic and cardiac monitoring Important measures during the first 24 hours of rt-PA treatment:  Vital signs and neurologic status: every 15 minutes for two hours, then every 30 minutes for six hours, then every 60 minutes until 24 hours from the start of rt-PA treatment  Blood pressure: at or below 180/105 mmHg during the first 24 hours  Anticoagulant and antithrombotic agents, such as heparin, warfarin, or antiplatelet drugs, should not be administered for at least 24 hours after the rt-PA infusion is completed.  Placement of intra-arterial catheters, indwelling bladder catheters, and nasogastric tubes should be avoided for at least 24 hours if the patient can be safely managed without them  A follow-up noncontrast CT (or MRI) brain scan: 24 hours after rt-PA is initiated before starting treatment with antiplatelet or anticoagulant agents

COMPLICATIONS Most complication: symptomatic intracerebral hemorrhage (5 to 7 percent) Additional complications: o Asymptomatic intracerebral hemorrhage o systemic bleeding o angioedema

symptomatic intracerebral hemorrhage sudden neurologic deterioration decline in level of consciousness new headache, nausea and vomiting sudden rise in blood pressure after thrombolytic therapy In these patients: Discontinuation of the rt-PA infusion noncontrast head CT or MRI scan Blood drawn for typing and cross matching measurement of PT, PTT, platelet count, and fibrinogen ● 10 units of cryoprecipitate to increase the levels of fibrinogen and factor VIII ● 6-8 units of platelets